Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dimeric immune fusion protein, pharmaceutical composition and application

A fusion protein and dimer technology, applied in the direction of drug combination, fusion polypeptide, peptide/protein components, etc.

Active Publication Date: 2020-04-17
PHARCHOICE THERAPEUTICS INC
View PDF7 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In summary, it is urgent to develop drugs that can remove intruders and inhibit the excessive production of cytokines in the body, and the inventors have not seen any reports of similar drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dimeric immune fusion protein, pharmaceutical composition and application
  • Dimeric immune fusion protein, pharmaceutical composition and application
  • Dimeric immune fusion protein, pharmaceutical composition and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] Example 1. Construction, expression and characterization of soluble dimer immune fusion protein

[0076] Such as figure 1 As shown, the soluble dimer immunofusion protein is a dimer with antibody Fc, and the method of constructing and expressing the dimer immunofusion protein itself is a routine experimental technique in the field, and a brief description is as follows:

[0077] (1) Entrust a gene synthesizer (Suzhou Jinweizhi Company) to optimize the coding nucleotide codon and complete gene synthesis for the amino acid sequence of the dimer immune fusion protein required in this example, and the optimized nucleotide sequence is directly loaded into On the PCDNA3.4 vector, the amino acid sequences encoded by all vectors are described in Table 1.

[0078] (2) Entrust the protein manufacturer (Shenzhou Yiqiao Co., Ltd.) to perform expression and purification of the dimeric immunofusion protein for this example. Using literature Finck B K. Science, 265.; Mihara M et al...

Embodiment 2 2

[0088] Embodiment 2 dimer immune fusion protein is to Staphylococcus aureus effect

[0089] Staphylococcus aureus expressing green fluorescent protein was collected from the Institute of Microbiology, Chinese Academy of Sciences, and the multiplicity of infection was 1:10. Peripheral blood samples were collected from healthy volunteers to separate peripheral mononuclear cells (PBMC, separated by Biyuntian Lymphocyte Separation Kit). Freshly isolated cells were stabilized in RPMI1640 medium containing 10% fetal bovine serum for 2 h (37.5°C, 5% CO 2 ).

[0090] Cultivate Staphylococcus aureus according to the experimental requirements, collect the bacteria by centrifuging at 10000g for 30 seconds in a desktop centrifuge, and resuspend to 10 8 Bacterial density around CFU / ml. Take the bacterial suspension for serial dilution plate counting to determine the exact bacterial density. After the PBMC cells replaced the medium, add 10 microliters of Staphylococcus aureus suspension...

Embodiment 3

[0098] Example 3 Immunodimer Effects on Methicillin-resistant Staphylococcus aureus

[0099] BALB / c mice, SPF grade, female, 6-8 weeks old, weighing 18-20 g, international standard strain MRSA-252, were purchased from American Tissue Culture Collection (ATCC). To establish a mouse model, inject 0.1 mL of the washed bacterial solution (the concentration of the bacterial solution is 1×10 9 CFU / mL), the mice in the blank group were injected with the same amount of sterile saline through the tail vein. The mice were then divided into a control group and a treatment group, with 10 mice in each group. The control group was given control IgG, and the treatment group was given a representative of the dimer immune fusion protein of the present invention at a dose of 10 mg / kg, administered intravenously. Inject once a day and observe continuously for 10 days. If any mice died or all mice were killed at the end of the last day of the experiment, the blood was plated immediately under a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of biomedical engineering, and provides a composition and a method related to soluble dimeric immune fusion protein. The dimeric immune fusion protein comprises a first dimerized polypeptide chain and a second dimerized polypeptide chain. The general structural formula of the first polypeptide chain is Z1-Z2, and the general structural formula of the second polypeptide chain is Y1-Y2. Z1 is (i) an extracellular domain of a first pattern recognition receptor or a functional variant or fragment thereof, or (ii) a functional variant or fragment thereofof a first co-receptor; and Z2 is a dimerized domain or a functional variant or fragment thereof. Y1 is (i) an extracellular domain of a second pattern recognition receptor or a functional variant orfragment thereof, or (ii) a second co-receptor or a functional variant or fragment thereof; and Y2 is a dimerized domain or a functional variant or fragment thereof. The dimeric protein provided by the invention can be used for blocking pathogen invasion and limiting generation and expansion of inflammatory mediators, and can be used for preparing products for preventing or treating inflammatorymediator-related diseases.

Description

technical field [0001] The invention relates to the technical field of biomedical engineering, in particular to a dimer immune fusion protein, a pharmaceutical composition using it as an active component and its medical application, especially the application for diseases related to inflammatory mediators. Background technique [0002] In animals, an inflammatory response occurs when cells or tissues are damaged by bacteria, trauma, toxins, physical or chemical factors (which may be collectively referred to as "inflammatory agents"). The pathophysiological features of the inflammatory response are regulated by the complex interplay of multiple pro-inflammatory or anti-inflammatory stimuli or mediators synthesized and released by cells. Some known classes of pro-inflammatory and anti-inflammatory stimuli or mediators include cytokines, nitrous oxide, thromboxane, aridine, phospholipid-like platelet activating factor, prostaglandins, elicitors, complement factors, coagulation ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00A61K38/17A61K47/68A61P1/16A61P11/00A61P13/12A61P15/00A61P15/06A61P29/00A61P31/04A61P31/10A61P31/12A61P31/14A61P33/00A61P33/10A61P37/02
CPCC07K14/70596C07K14/7056A61K47/68A61K47/6813A61P29/00A61P31/04A61P31/12A61P33/00A61P31/10A61P31/14A61P33/10A61P11/00A61P1/16A61P15/00A61P15/06A61P37/02A61P13/12C07K2319/00C07K2319/30A61K38/00
Inventor 傅文燕丁敏胡适
Owner PHARCHOICE THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com